| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot; human; 1:1000; loading ...; fig 4a
| Semaan L, Mander N, Cher M, Chinni S. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model. BMC Cancer. 2019;19:972 pubmed publisher |
- western blot; human; loading ...; fig 1c
| Shukla S, Cyrta J, Murphy D, Walczak E, Ran L, Agrawal P, et al. Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell. 2017;32:792-806.e7 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:5000; fig 3
| Marti N, Galvan J, Pandey A, Trippel M, Tapia C, Muller M, et al. Genes and proteins of the alternative steroid backdoor pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndrome. Mol Cell Endocrinol. 2017;441:116-123 pubmed publisher |
| Liu C, Yang J, Armstrong C, Lou W, Liu L, Qiu X, et al. AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer. Mol Cancer Ther. 2019;: pubmed publisher |
| Loiselle J, Knee J, Sutherland L. Human lung epithelial cells cultured in the presence of radon-emitting rock experience gene expression changes similar to those associated with tobacco smoke exposure. J Environ Radioact. 2019;196:64-81 pubmed publisher |
| Kawaguchi Y, Mizuno H, Horikawa M, Kano M, Yamada K, Yamakawa F, et al. Virilism and Ectopic Expression of HSD17B5 in Mature Cystic Teratoma. Tohoku J Exp Med. 2017;241:125-129 pubmed publisher |
| Liu C, Armstrong C, Lou W, Lombard A, Evans C, Gao A. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther. 2017;16:35-44 pubmed publisher |
| Abbattista M, Jamieson S, Gu Y, Nickel J, Pullen S, Patterson A, et al. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Cancer Biol Ther. 2015;16:610-22 pubmed publisher |
| Liu C, Lou W, Zhu Y, Yang J, Nadiminty N, Gaikwad N, et al. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res. 2015;75:1413-22 pubmed publisher |
| Mine N, Yamamoto S, Kufe D, Von Hoff D, Kawabe T. Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro. Mol Cancer Ther. 2014;13:2215-25 pubmed publisher |
| Huebbers C, Preuss S, Kolligs J, Vent J, Stenner M, Wieland U, et al. Integration of HPV6 and downregulation of AKR1C3 expression mark malignant transformation in a patient with juvenile-onset laryngeal papillomatosis. PLoS ONE. 2013;8:e57207 pubmed publisher |
| Catalano R, Wilson M, Boddy S, Jabbour H. Comprehensive expression analysis of prostanoid enzymes and receptors in the human endometrium across the menstrual cycle. Mol Hum Reprod. 2011;17:182-92 pubmed publisher |
| Breuiller Fouche M, Leroy M, Dubois O, Reinaud P, Chissey A, Qi H, et al. Differential expression of the enzymatic system controlling synthesis, metabolism, and transport of PGF2 alpha in human fetal membranes. Biol Reprod. 2010;83:155-62 pubmed publisher |
| Lin H, Steckelbroeck S, Fung K, Jones A, Penning T. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids. 2004;69:795-801 pubmed |
